- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01980901
Post-Approval Study of the Ovation™/Ovation Prime™ Abdominal Stent Graft System
A Post-Market Approved (PMA) Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation™/Ovation Prime™ Abdominal Stent Graft System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of the study is to demonstrate the long term safety and effectiveness of the Ovation™/Ovation Prime™ Abdominal Stent Graft System for the endovascular treatment of infrarenal abdominal aortic aneurysms in a post-approval environment.
The clinical objective of the study is to evaluate the long term safety and effectiveness of the Ovation™/Ovation Prime™ Abdominal Stent Graft System assessed at 5 years through freedom from Aneurysm-Related Mortality.
Additionally, this study will evaluate the physician training program for modifications based on IDE and post-approval experience.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Illinois
-
Champaign, Illinois, United States, 61820
- Christie Clinical Vein and Vascular Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
320 subjects enrolled with an estimated 192 evaluable subjects at the fifth year from the following cohorts:
- Available data from the 161 pivotal cohort subjects
- All Continued Access subjects;
- All subjects from the HDE PAS (reference H100008); and
- A minimum of 59 subjects from de novo enrollment.
Description
Inclusion Criteria:
- Patient is > 18 years of age.
- Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study).
- Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form.
- Patient is considered by the treating physician to be a candidate for elective open surgical repair of the AAA (i.e., category I, II, or III per American Society of Anesthesiology (ASA) classification; refer to Appendix III: ASA Classification System). ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year.
Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:
- Abdominal aortic aneurysm >5.0 cm in diameter
- Aneurysm has increased in size by 0.5 cm in last 6 months.
- Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment
- Patient has patent iliac or femoral arteries that allow endovascular access with the TriVascular Ovation/Ovation Prime Abdominal Stent Graft System.
- Patient has a suitable non-aneurysmal proximal aortic neck length of ≥ 7 mm inferior to the most distal renal artery ostium.
- Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥10 mm. The resultant repair should preserve patency in at least one hypogastric artery.
- Patient has a suitable non-aneurysmal proximal aortic neck luminal diameter between 16 and 30 mm.
- Patient has suitable non-aneurysmal distal iliac luminal diameters between 8 and 20 mm.
- Patient meets the following anatomic criteria: the distance from the most distal renal artery to most superior internal iliac artery measurement is at least 13 cm.
- Patient has juxtarenal aortic neck angulation ≤ 60º if proximal neck is ≥10 mm and ≤ 45º if proximal neck is <10 mm. Patient must be willing to comply with all required follow-up exams.
- Patient must be willing to comply with all required follow-up exams.
Exclusion Criteria:
- Patient has a dissecting aneurysm.
- Patient has an acutely ruptured aneurysm.
- Patient has an acute vascular injury.
- Patient has a need for emergent surgery.
- Patient has a known thoracic aortic aneurysm or dissection.
- Patient has a mycotic aneurysm or has an active systemic infection.
- Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina).
- Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 6 months.
- Patient has a major surgical or interventional procedure planned ≤30 days of the AAA repair.
- Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
- Patient has history of bleeding disorders or refuses blood transfusions.
- Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0 mg/dl
- Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
- Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers, fluorinated ethylene propylene (FEP) or nitinol.
- Patient has a body habitus that would inhibit X-ray visualization of the aorta
- Patient has a limited life expectancy of less than 1 year
- Patient is currently participating in an investigational device or drug clinical trial.
- Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ovation™/Ovation Prime™ Abdominal Stent Graft System
Adult male and female patients.
|
Single occurence permanent implant of AAA device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom From Aneurysm-Related Mortality at 5 Years
Time Frame: 5 Years
|
The primary endpoint of the Ovation™/Ovation Prime™ Abdominal Stent Graft System study will be determined by evaluating freedom from aneurysm-related mortality at five (5) years.
This will be compared to a target performance goal.
|
5 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite Safety and Performance Endpoints
Time Frame: 1 Month & Annually 1 to 5 Years
|
Serious Adverse Events (SAEs) within 30 days of the initial procedure and through 12 months and annually thereafter to 5 years At 30 days and 12 months and annually thereafter to 5 years, the following rates will be reported:
|
1 Month & Annually 1 to 5 Years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Syed Hussain, MD, Christie Clinical Vein and Vascular Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 771-0010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Aneurysm, Abdominal
-
Assistance Publique - Hôpitaux de ParisUnknownSmall Abdominal Aortic Aneurysm | Abdominal Aortic Aneurysm,France
-
EndologixActive, not recruiting1 Paravisceral Abdominal Aortic Aneurysm | 2 Juxtarenal Abdominal Aortic Aneurysm | 3 Pararenal Abdominal Aortic Aneurysm | 4 Complex Abdominal Aortic AneurysmsUnited States
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
Medtronic CardiovascularCompletedAbdominal Aortic Aneurysms (AAA)United States
-
Vascutek Ltd.TerminatedAbdominal Aortic Aneurysms (AAA)United Kingdom, Netherlands, Switzerland, Spain, Germany, Belgium, Sweden, Canada, France, Italy, Austria, Monaco
-
Washington University School of MedicineRecruitingAbdominal Aortic Aneurysm (AAA) | No Abdominal Aortic Aneurysm (Non-AAA)United States
-
Timothy Chuter, MDRecruitingThoracoabdominal Aortic Aneurysm | Paravisceral Abdominal Aortic AneurysmUnited States
-
University of California, San DiegoRecruitingJuxtarenal Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm | Pararenal Aortic Aneurysm | Complex Abdominal Aortic AneurysmUnited States
-
Assistance Publique Hopitaux De MarseilleCompletedAbdominal Aortic AneurysmsFrance
-
Hangzhou Endonom Medtech Co., Ltd.RecruitingJuxtarenal Abdominal Aortic AneurysmChina
Clinical Trials on Ovation™/Ovation Prime™ Abdominal Stent Graft System
-
TriVascular, Inc.CompletedAbdominal Aortic AneurysmBelgium, United Kingdom, Sweden, Austria, France, Germany, Greece, Italy
-
TriVascular, Inc.CompletedAortic Aneurysm, AbdominalUnited States
-
Larissa University HospitalUniversity Hospital of Crete; University of Patras; University Hospital, AlexandroupolisRecruiting
-
TriVascular, Inc.CompletedAbdominal Aortic AneurysmCanada
-
TriVascular, Inc.Completed
-
EndologixCompletedAortic Aneurysm, AbdominalUnited States
-
TriVascular, Inc.CompletedAbdominal Aortic AneurysmUnited States
-
TriVascular, Inc.Completed
-
TriVascular, Inc.Completed
-
Endospan Ltd.CompletedAortoiliac Aneurysms | Infrarenal Abdominal Aortic AneurysmsItaly, Serbia, Netherlands, Switzerland